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Abstract
Sarcoidosis is a systemic disease of unknown aetiology characterised by the formation of noncaseating granulomas in vari-
ous organs and tissues. The various imaging modalities that are useful in the investigation of lesions, staging and establishing 
indications for treatment include: conventional radiography, CT, MRI, and scintigraphy with 67Ga, 201Tl, 99mTc sestamibi, and 
somatostatin receptor scintigraphy (SRS) as well as 18F-FDG-PET/CT. This paper discusses the most commonly used technique 
of the scintigraphic, gallium (67Ga) citrate) and its role in the evaluation and monitoring of patients with sarcoidosis. 
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Background
Sarcoidosis is a systemic disease of unknown aetiology charac-
terised by the formation of noncaseating granulomas in various or-
gans and tissues. In about 90% of the patients, mediastinal and 
hilar lymph nodes and the pulmonary parenchyma are involved [1].
Systemic disease and multiple organs are frequently involved 
with a prevalence that varies from population to population though 
this may be related to the ability to identify sites of disease with 
the technology available to a particular patient group. For example 
cardiac sarcoidosis is discovered on autopsy in 13–25% of the 
patients in the USA, while clinical manifestations are present in 
about 5% of these patients. In Japan, cardiac sarcoidosis is found 
in as many as 58–85% of patients. Cutaneous involvement is seen 
in 20–35% of patients, ocular involvement in 10–60%, nervous sys-
tem involvement in about 5%, and musculoskeletal involvement in 
about 30%. In autopsy studies, hepatic involvement is seen in about 
50–80% of the patients, although its clinical manifestations are much 
less frequent. In 5% of patients, the pancreas is affected. Renal 
involvement is reported in 7–23% of subjects [1].
The systemic nature of the disease means that those tech-
niques which allow for whole body imaging are therefore more 
advantageous than those techniques such as in conventional 
radiography, ultrasound (US) and MRI, and to some extent CT. 
Radionuclide studies have the advantage that vertex to toe imaging 
is easily performed. This allows involvement in organs such as the 
brain and joints such as the knees and ankles to be assessed 
with a single investigation. Single photon agents which have been 
used to identify active sites of sarcoid with radionuclide studies, 
including conventional scintigraphy with 67Ga citrate, 201Tl chloride, 
99mTc sestamibi and somatostatin receptor scintigraphy (SRS) using 
agents such as 99mTc-HYNICTOC [2–5].
The evaluation of disease activity in patients with suspected 
or confirmed sarcoidosis is of utmost clinical significance. It al-
lows the establishing of indications for further management and 
pharmacotherapy and also when such treatment can be stopped 
as spontaneous remissions are observed in most patients. Though 
in a small percentage of patients, the clinical course of sarcoido-
sis may be severe and in some cases lead to death shortly following 
the diagnosis [6]. An accepted method of monitoring the activity 
of sarcoid is to look at the plasma angiotensin converting enzyme 
(ACE) level. When this is elevated at diagnosis this can be a very 
good method for monitoring disease activity with an expected 
reduction to a normal level in quiescent disease [7]. The major 
problem with use of the serum ACE is that in as many as 50% of 
patients levels are not elevated in active disease [8, 9]. In these 
patients the best alternate method is scintigraphy and at present 
the greatest evidence is for the use of 67Ga citrate scintigraphy.
Gallium (67Ga) citrate scintigraphy
In gallium (67Ga) scintigraphy a standard gamma camera 
is used, however, there are multiple energies emitted including 
those at 70 keV, 170 keV, 300 kev and 394 keV. Though the 394 keV 
has only a 4% abundancy it can cause significant septal penetration 
and scatter effect on the image unless a high energy collimator 
is used. This can reduce count rate, higher activity cannot normally 
be administered due to the poor dosimetry of 67Ga imaging so 
that an administered activity of 300 MBq gives an effective dose 
of 18 mSv which is the greatest radiation dose for any common 
radionuclide test. However, once injected imaging can be versatile 
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with planar, wholebody, SPECT (Single Photon Emission Computed 
Tomography) views being performed and more recently hybrid 
imaging combining SPECT and CT (SPECT/CT).
There is a variable physiological uptake of 67Ga. Initially there 
is high blood pool and urinary excretion is seen when the 67Ga 
is unbound [10, 11]. By 24 hours, however, most of the 67Ga 
is bound to transferrin and lactoferrin as it is an iron analogue. These 
proteins act as acute phase proteins and concentrate around the 
sites of focal infection and inflammation. There is also physiological 
activity in the liver and large intestine. The colonic activity can be very 
variable even within the same patients with no evidence that these 
changes in colonic activity has any pathological consequences. 
Slightly lower physiological uptake of the radiotracer is evident in the 
spleen, in the bone marrow (though in patients with activated bone 
marrow due to anaemia this bone marrow uptake can be intense), 
oral cavity and perineum. Other variants of physiological radiotracer 
uptake are associated with the activity of the glandular parenchyma 
of both breasts during the menstrual cycle, with a particularly high 
uptake being seen during lactation (such that following the admi-
nistration of 67Ga breastfeeding should be discontinued). There can 
be low grade uptake in lacrimal and salivary glands. Due to these 
physiological constraints image acquisition is usually performed 
48 hours after i.v. administration of the radiotracer. In exceptional 
cases, if unequivocal images are obtained after 48 hours, an ad-
ditional acquisition should be carried out after 72 hours, although 
this is not often done. Given the timing of radiotracer administration 
and the image acquisition that follows 48 hours later, the patient 
needs to come to the imaging facility twice.
Changes in thoracic lymph nodes and 
pulmonary parenchyma
In patients with sarcoidosis, the disease process most com-
monly affects hilar and mediastinal lymph nodes. Involvement 
is most commonly symmetrical, as is also evident on 67Ga citrate 
scintigraphy in the form of symmetrical radiotracer uptake over the 
lymph nodes of both hilar and the upper mediastinum producing the 
so called lambda sign (Fig. 1, 2) [12, 13]. The disease less frequently 
affects other local lymph node groups. This pattern of uptake is the 
most commonly seen in sarcoid and can be considered diagnostic 
Involvement of lymph nodes other than hilar and media-
stinal and unilateral involvement usually suggests a different 
diagnosis such as a well-differentiated Hodgkin or non-Hodgkin 
lymphoma, although in some cases it is caused by other rare 
diseases (e.g. IgG4-related disease) [14]. However as stated pre-
viously sarcoid uptake tends to be symmetrical, if there is doubt, 
however, biopsy of a 67Ga citrate avid node is diagnostic. The use 
of SPECT may allow the mediastinal and hilar nodal activity to be 
seen more clearly (Fig. 4). 
Of greater concern because it can carry a much worse prog-
nosis ins parenchymal diffuse uptake of 67Ga citrate uptake by the 
pulmonary parenchyma showing a diffuse (usually) pattern, but 
in some cases a geographic or even a focal pattern, which may 
suggest an alternate active inflammation or infectious process [15]. 
As the intensity of parenchymal lung disease can have an impact 
on patient survival it has been found useful to quantify the uptake 
of 67Ga citrate using the 5 point, Kramer scale originally used in pa-
tients with HIV but often re-applied to patients with sarcoid [16] (Table 1).
Figure 1. Whole-body (WB) 67Ga scintigraphy in the AP (A) and PA 
(B) views. Active sarcoidosis in a 50-year-old male. Involvement of the 
mediastinal lymph nodes and bilateral involvement of the hilar lymph 
nodes. High radiotracer uptake in the submandibular glands, less 
pronounced over the parotid and lacrimal glands. High radiotracer 
uptake over the matted axillary and inguinal lymph nodes and 
involvement of iliac lymph nodes, aortic bifurcation and inferior vena 
cava. Additionally evident skin lesions on both arms. The nodular and 
cutaneous form of sarcoidosis predominates 
A B
Figure 2. Whole-body (WB) 67Ga scintigraphy in a 38-year-old 
male with confirmed sarcoidosis in the AP (A) and PA (B) views. 
Pathologically high radiotracer uptake over the hilar lymph nodes 
bilaterally and over the mediastinal lymph nodes: the lambda 
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In 67Ga scintigraphy, increased radiotracer uptake by the 
lacrimal and parotid glands coupled with uptake by nasopharyn-
geal structures results in the characteristic “panda” sign (Fig. 2). 
Although this sign can also be seen in Sjögren syndrome, lym-
phomas (especially after head and neck radiotherapy), AIDS and 
IgG4-related disease, the sensitivity of this sign is 80% and 74% in 
patients with sarcoidosis in stage I and stage II, respectively. Ac-
cording to some authors, the sensitivity of the panda sign is even 
higher (96%), and in diseases other than sarcoidosis, e.g. IgG4-re-
lated disease, is only 62% [14]. At the same time, the presence of 
the panda sign and of the already discussed lambda sign is very 
characteristic of sarcoidosis [17–21]. There can be some confusion 
as there may be normal physiological uptake in the lacrimal and 
salivary glands and it may need experience to differentiate normal 
uptake from the elevated uptake seen in sarcoid.
Skeletal muscle
Muscles involvement in sarcoidosis is often asymptomatic 
and laboratory tests do not provide any indication of the possibil-
ity of this pathology either. Gallium scintigraphy is characterised 
by a high sensitivity in imaging superficial changes (located in 
skeletal muscles and skin) [12]. The increased radiotracer uptake 
by skeletal muscles observed on 67Ga scintigraphy is confirmed 
on MRI, which reveals changes consistent with sarcoid granulo-
mas in locations with increased radiotracer uptake [22]. Skeletal 
muscle involvement combined with the involvement of hilar and 
mediastinal lymph nodes, lacrimal glands and skin is manifested 
on 67Ga scintigraphy by a pattern that is sometimes called the 
dappled-body sign or leopard-man sign [23]. Remission of skeletal 
muscle changes as a result of glucocorticosteroid treatment is also 
visible on 67Ga scintigraphy [24]. 
Central nervous system
Central nervous system (CNS) involvement in sarcoidosis pa-
tients may manifest clinically by cranial nerve palsies, aseptic men-
ingitis, peripheral neuropathy (e.g. Guillain-Barre syndrome [25]) or 
myopathy. The diagnostic criteria for neurosarcoidosis published 
in 1999 are still in use [26].
The diagnosis of definite neurosarcoidosis (presence of 
non-caseating granulomas on histopathological examination of 
nerve tissue) is only possible in few patients [27]. Most cases carry 
the diagnosis of probable neurosarcoidosis, which depends on 
the clinical symptoms and signs and the diagnosis of sarcoid 
made from a non CNS site by biopsy or characteristic extra CNS 
lesions seen 67Ga citrate scintigraphy coupled with changes on 
MRI or in the cerebrospinal fluid suggestive of sarcoidosis. At the 
same time, histopathological examination of lesions outside the 
CNS reveals non-caseating granulomas that confirm the presence 
of sarcoidosis.
67Ga scintigraphy is therefore an auxiliary investigation in 
the diagnosis of sarcoidosis. In some cases, especially where 
no clinical manifestations are found outside the CNS, increased 
radiotracer uptake may indicate the optimal biopsy site and pro-
vide the highest likelihood of establishing the final pathological 
diagnosis [28, 29].
Lacrimal and salivary glands
As mentioned above, ocular changes are reported in 10–60% 
of sarcoidosis patients, depending on the author. They most 
commonly affect patients aged 20–40 years but can also be seen 
in children and the elderly. Their most common manifestation 
is uveitis [1]. Thirty percent of uveitis cases are associated with 
sarcoidosis and most commonly precede the onset of other mani-
festations of this disease [17].
The diagnostic criteria for ocular sarcoidosis (IWOS) include 
ocular changes in correlation with radiological studies (chest 
radio graphy and CT) and laboratory test results (plasma ACE if 
positive)  [17]. Increased 67Ga uptake by the lacrimal glands in 
patients with sarcoidosis is correlated with lacrimal gland biopsy 
results, which reveal non-caseating granulomas [18]. Involvement of 
parotid glands is reported in 6% of sarcoidosis patients [17, 19, 20].
Table 1. Kramer grading for intensity of lung uptake of 67Ga citrate
Grade Uptake intensity
0 No radiotracer uptake
1 Minimal uptake over structures other than those that show 
physiological radiotracer uptake
2 Uptake clearly visible but below the physiological high hepatic 
uptake
3 Uptake equal to the physiological hepatic uptake
4 Uptake above the physiological hepatic uptake
Figure 3. Whole-body (WB) 67Ga scintigraphy in the AP (A) and PA  
(B) views. Active sarcoidosis in a 54-year-old female patient with 
evident radiotracer uptake over the mediastinum and both lung zones
A B




Involvement of joints, which may be acute or chronic, is reported 
in 15–25% of sarcoidosis patients. Acute articular involvement most 
commonly occurs in the early stages of the disease and may be 
its first manifestation. Clinically, it takes the form of arthralgia, arthri-
tis or polyarthritis. Both wrists and ulnar joints are most commonly 
affected. The changes may migrate and are often accompanied 
by erythema nodosum [30]. 
Chronic joint disease associated with sarcoidosis is much 
less common or less frequently diagnosed due to its chronic na-
ture and relatively mild clinical manifestations compared to other 
symptoms of active sarcoidosis. It may be accompanied by skeletal 
muscle and bone involvement. It shows predilection for sacroiliac 
joints and spondyloarthritis [31, 32]. 
On 67Ga citrate scintigraphy, joint changes appear as areas of 
usually increased diffuse radiotracer uptake over the affected joint, 
usually including the articular capsule and synovium, usually with 
its hypertrophy and mild inflammation (Fig. 5).
Bone changes in sarcoidosis are often asymptomatic, al-
though in some patients, they can cause severe pain. Bones of the 
hands and feet are most commonly affected [31]. Radiographic 
and CT images reveal osteosclerotic or osteolytic lesions (the 
so-called lacy pattern) and are not specific for sarcoidosis. It should 
Figure 4. A SPECT scan in the transverse view (A), sagittal view (B) and coronal view (C) in the patient presented in Figure 2. The mediastinal 





Figure 5. Whole-body (WB) 67Ga scintigraphy in the AP view conducted in a 46-year-old male with active sarcoidosis (A) and a chest SPECT/CT 
scan in the coronal (B and C) and transverse (D and E) views in the same patient. Active pathology evident over the chest lesions: in the 
mediastinal lymph nodes and in both pulmonary hili. An evident panda sign in the lacrimal and salivary glands and the nasopharynx. Additionally, 
bilateral involvement of inguinal lymph nodes
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be emphasised that 67Ga scanning reveals any infectious and 
inflammatory changes, including tuberculosis in the lungs and 
other organs [32].
Heart
Cardiac involvement is the most common cause of death 
in patients with sarcoidosis in Japan (58–85% of the cases). 
The death rate in other countries is lower (eg. 13–25% in the 
United States) [1]. Cardiac sarcoidosis may manifest clinically 
as rhythm and conduction disorders (ventricular tachycardia [VT] 
or atrioventricular [AV] block) and congestive heart failure [33]. 
Cardiac involvement most commonly occurs before the age of 
50 years and is more common in women. While clinical mani-
festations of cardiac involvement occur in 2–7% of the patients, 
autopsy studies reveal sarcoid granulomas in 50% of the patients. 
It is therefore recommended that patients with both histologically 
detected extracardiac changes suggestive of sarcoidosis and 
clinical manifestations suggestive of cardiac involvement should 
be evaluated for this possibility [34].
The lesions in the heart are most commonly located in the 
interventricular septum and the inferior wall of the left ventricle. 
The scintigraphic diagnosis no longer depends on the use of 67Ga 
citrate scintigraphy in detecting cardiac lesions as the sensitivity 
is low (0–36%) [35], although in symptomatic patients with epi-
sodes of VT or AV block, it can be up to 80% [36]. The specificity 
Figure 6. Whole-body (WB) 67Ga scintigraphy in the AP (A) and the PA (B) views and a SPECT/CT scan in the transverse (C) and the coronal (D) 
views with SPECT and CT image fusion. Active sarcoidosis in a 38-year-old male. Evident involvement of the salivary glands, nasopharynx and 
lacrimal glands (the panda sign). Additionally, evident pathology in the mediastinum and both pulmonary hili: nodal lesions (the lambda sign). 
Diffuse, slightly increased radiotracer uptake over both lung zones. Bilateral involvement of inguinal lymph nodes. Additionally, involvement of 
sacroiliac joints in the course of sarcoidosis, more on the left than on the right
A B
C D
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is, however, very high (94–100%) [34]. Increased 67Ga uptake 
by sarcoid granulomas may predispose to a good response to 
corticosteroids [37].
67Ga scans performed in patients during treatment of sar-
coidosis with systemic steroids reveal a decrease in radiotracer 
uptake by the lesions as a result of the treatment. This can be seen 
as early as 30 days into treatment [31, 32]. Such differences are 
not observed in heart scintigraphy with 201Tl or 99mTc MIBI [37–39].
The recommended method for diagnosis of cardiac sarcoid 
is to perform 18F-FDG, though this needs preparation with a low 
carbohydrate high glucose diet for 48 hours post scan. Focal uptake 
of 18F FDG is seen in the presence of cardiac sarcoid but can only 
be used in the presence of normal myocardial perfusion.
Kidneys
Renal involvement in sarcoidosis may manifest by nephrolithiasis, 
nephrocalcinosis, nephrogenic diabetes insipidus, acute interstitial 
nephritis, granulomatous pseudotumour, and renal failure [1, 40]. 
There is little published data on the role of 67Ga scintigraphy in the 
evaluation of renal changes. Isolated case reports indicate that 
patients with renal involvement do not reveal increased renal uptake 
of 67Ga, which is contradicted by our yet unpublished findings of 
increased radiotracer uptake over the affected kidneys [40, 41].
Pathologically increased 67Ga uptake by the kidneys in a female 
patient with sarcoidosis is illustrated in Figures 6A and 6B.
Has 67Ga citrate imaging a future in the time 
of PET
There is increasing evidence that 18F-FDG may be more ac-
curate than 67Ga citrate and pick up unsuspected sites of disease 
[42–44]. In a prospective comparative study 18 patients with sarcoid 
was imaged with both 18F-FDG and 67Ga citrate. The sensitivity of 
67Ga citrate in the lungs was 84% compared to 100 with 18F-FDG. 
In extra-pulmonary disease the sensitivity of 67Ga citrate was 48% 
compared to 90% with 18F-FDG [45]. 18F-FDG was also noted to 
predict clinical response to treatment faster than changes in 67Ga 
citrate. European and North American guidelines confirm that 
the overall accuracy of 18F-FDG PET in studies including 173 pa-
tients [46]. Whilst 18F-FDG seems the more accurate test in many 
countries there is no reimbursement for PET in sarcoidosis so until 
that time it is unlikely to replace 67Ga citrate imaging 
Conclusion
67Ga citrate scintigraphy has been used is sarcoidosis for over 
30 years. Imaging is improved by the use of SPECT and SPECT-CT 
and can find and determine the activity of the patient’s sarcoid in 
all but some cases of neurosarcoid and may be essential when the 
serum ACE is unhelpful. Many recent publications have compared 
the sensitivity and specificity of 18FDG-PET/CT with those of 67Ga, 
revealing superiority of the former. Until PET imaging in sarcoid 
is reimbursed. 67Ga citrate scintigraphy remains the scintigraphic 
method of choice in sarcoid. 
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